Sana Biotechnology Announces Aggregate Sales Of 21,607,878 Shares With Net Proceeds Of ~$69M Through Its ATM Facility Established With TD Securities

The investment, including participation based on interest received from RA Capital Management, combined with the previously announced unrelated $25 million investment from the Mayo Clinic, brings the total capital raised since the end of the first quarter of 2026 to approximately $94 million and extends the company's expected cash runway to mid-2027.

The shares of common stock described above were sold by the company pursuant to an automatically effective shelf registration statement on Form S-3ASR (File No. 333-293981), including the ATM prospectus supplement, filed by the company with the SEC on March 3, 2026. The ATM prospectus supplement and the accompanying prospectus may be obtained from TD Securities (USA) LLC, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com. Electronic copies of the ATM prospectus supplement and the accompanying prospectus are also available on the SEC's website at http://www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.